circle

INVESTORS & MEDIA

CYTOKINETICS IN THE NEWS

Here you can find the latest articles about Cytokinetics, along with fact sheets describing the company, our clinical programs and background on our areas of disease focus – ALS, heart failure and SMA.

Date

Title

 

September 22, 2021, By Erik Swain Healio’s Cardiology Today
August 11, 2021, Neurology Live Phase 3 Trial of Reldesemtiv in ALS Announced
August 12, 2021, Bloomberg Cytokinetics CEO Robert Blum on Biopharma Outlook
July 19, 2021, Barron's Cytokinetics Stock Is Surging. Heart-Drug Results Are Exciting Investors
July 19, 2021, Endpoints UPDATED: Cytokinetics is getting its shot at a major PhIII showdown with Bristol Myers after posting positive data for a rare cardio disease. Shares rocket up
July 12, 2021, San Mateo Daily Journal Cytokinetics closes in on innovative heart drug
May 18, 2021, TCTMD Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs
May 17, 2021, Fierce Biotech ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure
November 17, 2020, Clinical Trial Results TV Dr. John Teerlink and Dr. C. Michael Gibson Discuss: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction
November 13, 2020, Scrip Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients
November 13, 2020, BioCentury Cytokinetics sees path to market for omecamtiv mecarbil in more severe heart failure patients
November 13, 2020, Cardiology Today Omecamtiv mecarbil lowers CV death/HF events in HFrEF: GALACTIC-HF
November 10, 2020, CEO Magazine The long, patient journey: Robert Blum
August 20, 2020, CNBC Fast Money Under-the-radar biotech name is up 120% this year
July 14, 2020, Endpoints News Cytokinetics nabs Chinese partner, up to $450M as CV becomes company focus
July 14, 2020, San Francisco Business Times Biotech legends help launch parasite-fighting startup with deep Stanford ties
March 5, 2020, ALS News Today Reldesemtiv Wins EMA Orphan Drug Designation for ALS Treatment

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )